RTTNews | Sep 15, 2021 10:06AM EDT

10:05 Wednesday, September 15, 2021 (RTTNews.com) - Shares of Indaptus Therapeutics, Inc. (INDP) more than doubled on Wednesday morning after the pre-clinical stage biotech company received notice of allowance from the U.S. Patent and Trademark Office for a strategic patent.

INDP is currently trading at $15.85, up $8.78 or 124.25%, on the Nasdaq, on a volume of 35.7 million shares, far above average volume of 925 thousand shares. The stock has traded between $6.84 and $36.80 in the 52 week period.

Indaptus Therapeutics said it thePatent and Trademark Office issued a notice of allowance for claims related to the company's platform technology. The patent, titled, "Methods of Treatment of Infections Using Bacteria," provides broad protection for the application of the company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

Indaptus Therapeutics develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases.

Read the original article on RTTNews ( https://www.rttnews.com/3225953/indaptus-therapeutics-shares-soar-125-after-it-gets-notice-of-allowance-from-us-patent-office.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved